310 related articles for article (PubMed ID: 22269894)
1. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
Cheng AL; Shen YC; Zhu AX
Oncology; 2011; 81(5-6):372-80. PubMed ID: 22269894
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of hepatocellular carcinoma: present and future.
Chan SL; Yeo W
J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
[TBL] [Abstract][Full Text] [Related]
3. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
4. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
5. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
6. Signaling pathways in hepatocellular carcinoma.
Sia D; Villanueva A
Oncology; 2011; 81 Suppl 1():18-23. PubMed ID: 22212931
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
Kudo M
Dig Dis; 2011; 29(3):289-302. PubMed ID: 21829020
[TBL] [Abstract][Full Text] [Related]
8. Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Kudo M
Dig Dis; 2011; 29(3):316-20. PubMed ID: 21829023
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies for hepatocellular carcinoma.
Skelton MR; O'Neil B
Clin Adv Hematol Oncol; 2008 Mar; 6(3):209-18. PubMed ID: 18391920
[TBL] [Abstract][Full Text] [Related]
11. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
Rimassa L; Santoro A
Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
[TBL] [Abstract][Full Text] [Related]
12. Molecularly targeted therapy in hepatocellular carcinoma.
Huynh H
Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
14. [Hepatocellular carcinoma].
Kondo S; Ueno H; Morizane C; Okusaka T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
17. Growth factors as therapeutic targets in HCC.
Furuse J
Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
19. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors to treat liver cancer.
Huynh H
Expert Opin Emerg Drugs; 2010 Mar; 15(1):13-26. PubMed ID: 20128706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
